lactic acid has been researched along with Foot Dermatoses in 11 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "Onychomycosis is difficult to cure as this requires eradication of the primary infection and protection of new areas of growth from reinfection." | 6.77 | Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. ( Emtestam, L; Kaaman, T; Rensfeldt, K, 2012) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "Onychomycosis is difficult to cure as this requires eradication of the primary infection and protection of new areas of growth from reinfection." | 2.77 | Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. ( Emtestam, L; Kaaman, T; Rensfeldt, K, 2012) |
| " Ninety-two patients were enrolled; 41 of these were excluded from analysis (25 were lost to follow-up, 8 were noncompliant, 1 was discharged from study because of an adverse event after visit 1, and 7 were noncompliant after visit 2)." | 2.71 | A double-blind clinical trial comparing the efficacy and safety of pure lanolin versus ammonium lactate 12% cream for the treatment of moderate to severe foot xerosis. ( Alfieri, DM; Goodwin, S; Jackman, L; Jennings, MB; Lesczczynski, C; Parker, ER, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angamuthu, M | 1 |
| Nanjappa, SH | 1 |
| Raman, V | 1 |
| Jo, S | 1 |
| Cegu, P | 1 |
| Murthy, SN | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Emtestam, L | 1 |
| Kaaman, T | 1 |
| Rensfeldt, K | 1 |
| Jennings, MB | 3 |
| Alfieri, DM | 2 |
| Parker, ER | 1 |
| Jackman, L | 1 |
| Goodwin, S | 2 |
| Lesczczynski, C | 3 |
| Siskin, SB | 1 |
| Quinlan, PJ | 1 |
| Finkelstein, MS | 1 |
| Marlucci, M | 1 |
| Maglietta, TG | 1 |
| Gibson, JR | 1 |
| Alfieri, D | 1 |
| Ward, K | 1 |
| Uy, JJ | 1 |
| Joyce, AM | 1 |
| Nelson, JP | 1 |
| West, B | 1 |
| Montague, JR | 1 |
| Logan, L | 1 |
| Ross, CF | 1 |
| Ademola, J | 1 |
| Frazier, C | 1 |
| Kim, SJ | 1 |
| Theaux, C | 1 |
| Saudez, X | 1 |
| Pham, HT | 1 |
| Exelbert, L | 1 |
| Segal-Owens, AC | 1 |
| Veves, A | 1 |
| Auken, G | 1 |
| Gade, M | 1 |
| Pilgaard, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes -a Randomized Controlled Trial[NCT02641548] | 120 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
10 trials available for lactic acid and Foot Dermatoses
| Article | Year |
|---|---|
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antifungal Agents; Double-Blind Method; Dru | 2012 |
A double-blind clinical trial comparing the efficacy and safety of pure lanolin versus ammonium lactate 12% cream for the treatment of moderate to severe foot xerosis.
Topics: Administration, Topical; Adult; Aged; Double-Blind Method; Drug Combinations; Female; Follow-Up Stud | 2003 |
The effects of ammonium lactate 12% lotion versus no therapy in the treatment of dry skin of the heels.
Topics: Adult; Aged; Aged, 80 and over; Foot Dermatoses; Heel; Humans; Lactates; Lactic Acid; Middle Aged | 1993 |
Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; D | 1998 |
Ammonium lactate 12% lotion versus a liposome-based moisturizing lotion for plantar xerosis. A double-blind comparison study.
Topics: Adolescent; Adult; Aged; Antipruritics; Double-Blind Method; Emollients; Foot Dermatoses; Humans; La | 1999 |
A comparative study of lactic acid 10% and ammonium lactate 12% lotion in the treatment of foot xerosis.
Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; Erythema; Female; Foot Der | 2002 |
Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedul | 2002 |
A prospective, randomized, controlled double-blind study of a moisturizer for xerosis of the feet in patients with diabetes.
Topics: Aged; Diabetic Foot; Double-Blind Method; Emollients; Female; Foot Dermatoses; Humans; Lactic Acid; | 2002 |
[Treatment of warts of the hands and feet with Verucid].
Topics: Clinical Trials as Topic; Copper; Drug Combinations; Foot Dermatoses; Hand Dermatoses; Humans; Lacti | 1975 |
1 other study available for lactic acid and Foot Dermatoses
| Article | Year |
|---|---|
Controlled-release injectable containing terbinafine/PLGA microspheres for onychomycosis treatment.
Topics: Antifungal Agents; Delayed-Action Preparations; Foot Dermatoses; Humans; Injections; Lactic Acid; Mi | 2014 |